We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Rahul
Mahida
r.mahida@bham.ac.uk
Dr
Rahul
Mahida
r.mahida@bham.ac.uk
Dr
Rahul
Mahida
r.mahida@bham.ac.uk
Other bacterial diseasesOther respiratory diseases principally affecting the interstitium
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
When some people have a severe infection, their body's defence systems can over-react and damage their own organs through inflammation. In the lungs, we term this process Acute Respiratory Distress Syndrome (ARDS). ARDS causes the lungs to fill up with water, making it very difficult to breathe. These patients are looked after in the intensive care unit (ICU), where a machine can support their breathing. The death rate associated with this is 40%.
Cells within the body can form outpouchings which break off to form extra-cellular vesicles (EVs). These EVs carry genetic material between different cell types and can affect how cells function.
We know that lung defender cells (alveolar macrophages) in patients with ARDS do not work as well as in healthy people. Their ability to clear away dead cells is weakened, leading to increased inflammation, and risk of death. We want to determine whether transfer of genetic material by EVs to these defender cells may contribute to inflammation in ARDS.
Seriously ill patients who require breathing machine support and who have sepsis (with or without ARDS) will be eligible for this study. Patients will be recruited from the ICU of the University Hospitals Birmingham NHS Trust. Study involvement will last up to 1 month for each patient. Participation in this study will not affect the clinical care that patients receive; however additional samples of blood, urine and lung washings will be taken for research purposes. These samples are also routinely taken as part of normal clinical care in the ICU.
We will treat healthy defender cells with EVs derived from patient samples, to see if this reduces their ability to clear away dead cells. We will then determine what genetic material is transferred by the EVs, and whether preventing this will restore defender cell function and reduce inflammation.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
1) Imminent Treatment withdrawal 2) Clinically relevant immunosuppression (for any reason) prior to current acute illness 3) Personal Consultee, when available, does not provide assent 4) Designated Consultee, if used, does not provide assent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Rahul
Mahida
r.mahida@bham.ac.uk
Dr
Rahul
Mahida
r.mahida@bham.ac.uk
Dr
Rahul
Mahida
r.mahida@bham.ac.uk
The study is sponsored by University of Birmingham and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 54571
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
